Compare · MDLN vs TNDM
MDLN vs TNDM
Side-by-side comparison of Medline Inc. (MDLN) and Tandem Diabetes Care Inc. (TNDM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and TNDM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $47.21B, about 45.0x TNDM ($1.05B).
- Over the past year, MDLN is down 11.9% and TNDM is down 24.5% - MDLN leads by 12.6 points.
- MDLN has been more active in the news (18 items in the past 4 weeks vs 10 for TNDM).
- Both have 25 recent analyst ratings on file.
- Company
- Medline Inc.
- Tandem Diabetes Care Inc.
- Price
- $35.91-1.41%
- $15.27-0.72%
- Market cap
- $47.21B
- $1.05B
- 1M return
- -4.76%
- +10.25%
- 1Y return
- -11.88%
- -24.52%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2013
- News (4w)
- 18
- 10
- Recent ratings
- 25
- 25
Tandem Diabetes Care Inc.
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. Its products in development include t:sport insulin delivery system; and connected (mobile) health offerings. Tandem Diabetes Care, Inc. has a development and commercialization agreement with Dexcom, Inc. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Latest MDLN
- Officer Abrams William J covered exercise/tax liability with 1,308 shares, decreasing direct ownership by 7% to 16,546 units (SEC Form 4)
- Chief Human Resources Officer Shryock Christopher P covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Operating Officer Miller Stephen L covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
- Chief Legal Officer Liberman Alexander M. covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Product Officer Laabs Amanda H. covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
- Chief Financial Officer Drazin Michael B covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
- Chief Commercial Officer Golwas Douglas P covered exercise/tax liability with 1,889 shares, converted options into 100,000 shares, sold $3,677,115 worth of shares (100,000 units at $36.77) as part of a pre-agreed trading plan and returned 100,000 units of Class B Common Stock to the company, increasing direct ownership by 1,319% to 365,864 units (SEC Form 4)
- Chief Executive Officer Boyle James M covered exercise/tax liability with 2,370 shares, decreasing direct ownership by 7% to 29,369 units (SEC Form 4)
- Director Galanti Richard A was granted 16,392 shares (SEC Form 4)
- Director Sweet Thomas W was granted 17,800 shares (SEC Form 4)
Latest TNDM
- Tandem Diabetes Care Automated Insulin Delivery Systems Receive CE Mark for Type 2 Diabetes and Type 1 Diabetes During Pregnancy
- EVP, Chief Strategy Officer Gasser Elizabeth Anne gifted 7,160 shares and received a gift of 7,160 shares, closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by PRESIDENT & CEO Sheridan John F
- SEC Form 4 filed by EVP, Chief Strategy Officer Gasser Elizabeth Anne
- SEC Form 4 filed by EVP & CHIEF FINANCIAL OFFICER Vosseller Leigh
- SEC Form 4 filed by EVP & Chief Operating Officer Kyrillos Jean-Claude
- SEC Form 4 filed by EVP & Chief Legal Officer Hansen Shannon Marie
- SEC Form 4 filed by EVP & Chief Admin. Officer Morrison Susan
- SEC Form 4 filed by EVP & Chief Technology Officer Carpenter Rick
- Tandem Diabetes Care upgraded by Wells Fargo with a new price target